PanTher Therapeutics

PanTher Therapeutics is a clinical-stage oncology company offering transformational localized treatment of cancer. This is accomplished through its proprietary SagittariTM platform which enables continuous, high-dose treatment of potent oncology agents exclusively at the site of a tumor. The SagittariTM treatment platform is a revolutionary solution for local administration of therapeutic agents. This foundational technology was invented at the Massachusetts Institute of Technology by PanThers founder and CEO. Sagittari is a polymer-based system that allows therapeutic agents to be formulated in a wide range of dosage forms that can be administered to the surface of a cancerous organ or implanted directly into a tumor. The drug product is designed to continuously deliver drug for weeks or months at a desired dose level, without unwanted dose-limiting side effects. PanThers lead clinical candidate, PTM-101, has successfully been evaluated in a Phase 1 clinical trial in treatmen...